AEON Biopharma, Inc. Class A

Stage 4 · Declining · week 21

As of Oct 22, 2026, AEON Biopharma is in Stage 4, the downtrend phase, now in week 21 (since May 27, 2026). It closed at $0.23, 82.8% below its 52-week high and below its 200-day average, which is falling.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. More about the company

$0.23

-2.62% today

$11.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is AEON early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 43w

S4 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 9w → S4 4w → S1 2w → S4 5w → S1 5w → S2 10w → S3 4w → S4 11w → S1 1w → S4 43w → S1 12w → S4 4w → S1 8w → S2 3w → S3 1w → S2 12w → S3 8w → S4 21w current

Total tracked: 165 weeks across 18 stage runs.

AEON among Biotechnology461st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…461	AEONAEON Biopharma, Inc. Class A	Stage 4 · wk 21	12	−11.4%

vs 52W High

-82.8%

$0.19 lo$1.36 hi

82.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 21

1w13w26w

Week 21, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-66.7%

200 DMA: $0.70 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.01x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-11.4%

-6.8%

-77.5%

YTD

-78.9%

-79.3%

Scan Membership

Breakout Watch

Latest: 2024-02-12

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 21 · Vol 0.01x

2026-10-21S4

Wk 21 · Vol 0.02x

2026-10-20S4

Wk 21 · Vol 0.03x

2026-10-19S4

Wk 21 · Vol 0.05x

2026-10-16S4

Wk 20 · Vol 0.03x

2026-10-15S4

Wk 20 · Vol 0.04x

2026-10-14S4

Wk 20 · Vol 0.12x

2026-10-13S4

Wk 20 · Vol 0.14x

2026-10-12S4

Wk 20 · Vol 0.11x

2026-10-09S4

Wk 19 · Vol 0.17x

2026-10-08S4

Wk 19 · Vol 0.12x

2026-10-07S4

Wk 19 · Vol 0.31x

Moving averages & range

50 DMA

$0.26

200 DMA

$0.70

52W High

$1.36

52W Low

$0.19

5D Low

$0.23

Resistance levels (recent highs)

20d High

$0.31

60d High

$0.33

120d High

$0.95

250d High

$1.36

Next resistance

+32.9%

to 20d High

Dividend Yield

0.00%

P/B -0.4

AEON Biopharma: quick answers

What stage is AEON Biopharma in?

As of Oct 22, 2026, AEON Biopharma (AEON) is in Stage 4, the downtrend phase. It entered Stage 4 on May 27, 2026 and is in week 21. What the four stages mean

Is AEON Biopharma in an uptrend?

No. AEON Biopharma is in a Stage 4 downtrend. It trades 66.7% below its 200-day average, which is falling.

How far is AEON Biopharma from its 52-week high?

AEON Biopharma closed at $0.23 on Oct 22, 2026, 82.8% below its 52-week high of $1.36. Its 52-week low is $0.19.

How has AEON Biopharma performed over the past year?

As of Oct 22, 2026, AEON Biopharma is down 79.3% over the past year and down 78.9% so far in 2026.

Which sector and industry is AEON Biopharma in?

AEON Biopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.